Key result
Coronary IVL yields an 11% 1-year MACE rate, with procedural complications predicting higher risk.
Why the study?
Intravascular lithotripsy is a viable treatment for calcified coronary lesions, but clinical and procedural factors associated with major adverse cardiovascular events following IVL needed identification.
Cohort (n=583)
Yes
In a real-world registry of patients undergoing coronary intravascular lithotripsy, clinical outcomes were favorable, with procedural complications, complex lesion types, and greater residual stenosis identified as predictors of MACE.
Supports risk stratification by lesion complexity and procedural factors in IVL; leaves open whether targeted optimization reduces MACE pending prospective trials.
Intravascular lithotripsy (IVL) has emerged as a viable treatment option for calcified coronary lesions. This study aimed to identify clinical and procedural factors associated with major adverse cardiovascular events (MACE) following IVL. This retrospective analysis included 583 patients (72.9 ± 9 years, 74% male) treated with IVL for 612 lesions from the multicenter BENELUX-IVL registry (May 2019-December 2024). Kaplan-Meier analysis was performed to evaluate survival probability. Binary logistic regression analysis was performed to identify predictors of MACE, including cardiac death, nonfatal myocardial infarction (MI) or clinically driven target vessel revascularization (TVR) at 1-year follow-up. Patients presented with acute coronary syndrome in 246 cases (42%), while a variety of target lesions was treated, including in-stent lesions (n = 185, 30%), aorta-ostial lesions (n = 148=24%), bifurcation lesions (n = 135, 22%) and chronic total occlusions (CTOs)(n = 45, 7%). MACE occurred in 44 patients (11%) at 1-year and in 53 patients (18%) at 2-years follow-up. Occurrence of procedural complications (p <0.001), CTOs (p = 0.020), in-stent lesions (p = 0.044), post-IVL plaque modification (p = 0.003) and greater postprocedural residual diameter stenosis on fluoroscopy (p = 0.006) were associated with the occurrence of MACE, while MI in the medical history (p = 0.001) was negatively associated with MACE. Following treatment with IVL in a real-world registry, clinical outcomes up to 2-years follow-up were favorable. Procedural complications, CTOs, in-stent lesions, performance of post-IVL plaque modification and greater postprocedural residual diameter stenosis on fluoroscopy were independent risk factors for experiencing MACE at 1-year follow-up. In contrast, a history of MI was associated with a lower risk of MACE.
No takes yet. Share an insight, caveat, or question.
Phagu et al. (2025) conducted a cohort in Calcified coronary lesions (n=583). Intravascular lithotripsy (IVL) was evaluated on Major adverse cardiovascular events (MACE), including cardiac death, nonfatal myocardial infarction (MI) or clinically driven target vessel revascularization (TVR) at 1-year follow-up. In 583 patients treated with intravascular lithotripsy for calcified coronary lesions, MACE occurred in 11% at 1 year and 18% at 2 years, with procedural complications predicting higher risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: